Policy Considerations February 21, 2018

Q1a. Hepatitis A vaccines should administered for post-exposure prophylaxis for all persons age ≥12 months.

Q1b. In addition to hepatitis A vaccine, IG may be administered to persons age >40 years depending on the providers risk assessment.

Provider Guidance

- Factors to consider in the decision to use IG in addition to vaccine
 - Age
 - Immune status and underlying conditions
 - Exposure type (risk of transmission)
 - Availability of IG

Q2. Hepatitis A vaccine should be administered to infants age 6-11 months of age traveling outside the United States when protection against hepatitis A is recommended

Workgroup Considerations

- "All persons aged ≥6 months who plan to travel or live abroad should ensure that they have acceptable evidence of immunity to measles, rubella, and mumps before travel. Travelers aged ≥6 months who do not have acceptable evidence of measles, rubella, and mumps immunity should be vaccinated with MMR vaccine. Before departure from the United States, children aged 6 through 11 months should receive 1 dose of MMR vaccine..."1
- Immune globulin and MMR vaccine should not be administered simultaneously.
- Therefore, infants aged 6-11 months who will be traveling internationally who also need protection against hepatitis A should receive a single dose of HepA vaccine.
- Infants should then start the 2-dose series of MMR and HepA vaccines at ≥12 months of age as recommended.

Q1a. Hepatitis A vaccines should be administered for post-exposure prophylaxis for all persons age ≥12 months.

Q1b. In addition to hepatitis A vaccine, IG may be administered to persons age >40 years depending on the providers' risk assessment.

Q2. Hepatitis A vaccine should be administered to infants age 6-11 months traveling outside the United States when protection against hepatitis A is recommended.